Brief: Clover Biopharmaceuticals Plans To Complete Development Of Its Covid-19 Vaccine Candidate As A Universal Covid-19 Booster Vaccine In 2022
14/02/2022 14:20
Feb 14 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* PLANS TO COMPLETE DEVELOPMENT OF ITS COVID-19 VACCINE
CANDIDATE
AS A UNIVERSAL COVID-19 BOOSTER VACCINE IN 2022
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune